Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Cortland Biomedical Expands Braiding Capabilities with New Flat and Round-Flat-Round Braiders to Drive Medical Device Innovation

Cortland Biomedical

Cortland Biomedical, a full-service biomedical textile product development partner that provides access to a full spectrum of custom engineering services, has expanded its braiding capabilities with the addition of flat braiding and round-flat-round braiding equipment. This latest investment provides Cortland Biomedical’s OEM customers with access to a full suite of braiding technologies, further strengthening the company’s position as a trusted partner enabling less invasive medical devices across a range of surgical applications. Braids plays a critical role in the design and performance of implantable medical textiles, particularly for orthopedic and sports medicine applications such as tendon and ligament repair. Flat braiding enables precise control over width and thickness, offering enhanced customization for applications requiring flexible yet strong structures that are able to distribute and bear force effectively. Meanwhile, round-flat-round braiding allows for seamless transitions between different braid geometries, optimizing load distribution and mechanical properties essential for next-generation medical devices. This unique structure enables a needle to be attached to the round section or tip, providing additional functionality. “With the addition of these new braiders, we are expanding the design possibilities for our customers, giving them even greater flexibility in developing high-performance biomedical textiles,” said Wesley Conger, engineering director, Cortland Biomedical. “This investment underscores our commitment to delivering custom textile solutions that meet the evolving needs of the medical device industry.” The expanded capabilities complement Cortland Biomedical’s existing expertise in braiding – which already included low and high density braiding, and branch braiding -- as well as woven, knitted, and other advanced textile engineering solutions. By offering a comprehensive range of biomedical textile technologies, the company continues to support OEMs in accelerating innovation and improving patient outcomes. About Cortland Biomedical Cortland Biomedical – which is now FDA registered -- custom designs and manufactures high-performance biomedical textile structures leveraging years of experience in medical textile engineering methods including knitting, braiding and weaving. Its thoughtful design concepts challenge the status quo. Cortland Biomedical’s unique combination of advanced equipment and technology, a seasoned medical textile engineering team, and first-rate R&D capabilities allows it to tackle customers’ complex challenges with the innovation and agility expected in the medical device industry. Learn more at cortlandbiomedical.com. Contact Details Jordan Bouclin, SVM Public Relations +1 401-490-9700 Jordan.bouclin@svmpr.com Company Website https://www.cortlandbiomedical.com/

March 19, 2025 10:00 AM Eastern Daylight Time

Centre For Neuro Skills to Open Clinic in Plano; Fifth in Texas

Centre for Neuro Skills

Centre for Neuro Skills (CNS), a premier provider of treatment for traumatic and acquired brain injury, today announced the opening of its new clinic in Plano, Texas. CNS’ approximately 20,000 square ft. facility at 1649 Dallas Parkway will open to new patients in winter 2025-2026. “Over the past few years, we’ve seen population growth in the North Dallas area, with Plano being one of the fastest growing regions,” said David Harrington, CEO of CNS. “We are increasing our footprint in Texas to meet the high demand for our facilities and individualized services to bring high-quality post-acute care to not only North Texas but also neighboring states like Oklahoma.” Patient-centered approach to treating brain injury CNS, highly regarded for its expertise in brain injury and stroke treatment as well as its experienced staff. Three of CNS’ clinics, including one in Irving, recently received accreditation by the Behavioral Health Center of Excellence for demonstrating its commitment to the standards of excellence for applied behavior analysis services. As CNS’ fifth Texas location, the Plano clinic will deepen the post-acute care provider’s commitment to the Dallas Healthcare community and the state. CNS’ Plano location’s many advanced-care features include: Programs for vision, neurobehavior, cognitive retraining, speech, physical and occupational therapy provided by highly trained and certified clinical therapy staff The ZeroG® Gait and Balance System Bioness Integrated Therapy System (BITS), used to aid in vision, motor and balance training Individualized counseling as well as family counseling (a hallmark of CNS support) Opportunities to participate in cutting edge brain injury and stroke research Brain injury and its devastating and costly effects Traumatic brain injury (TBI) is caused by blunt, traumatic forces to the brain. Acquired Brain Injury (ABI) is a non-traumatic brain injury or disease such as stroke, encephalitis or other infectious diseases, anoxic/hypoxic injury (lack of oxygen to the brain), aneurysms, seizure disorders, surgical procedures and toxic exposure. According to the Brain Injury Association of America, 2.9 million Americans visit the emergency department due to a TBI every year. According to the Texas Brain Injury Alliance: 144,000 Texans sustain a TBI each year — one every 4 minutes More than 381,000 Texans live with a disability due to a TBI — 2% of the population More than 5,700 Texas residents are permanently disabled by TBI each year Convenient Location CNS’ new clinic offers space to accommodate a broader population of inpatient, outpatient, day treatment and residential post-acute brain injury patients. It is adjacent to the Dallas North Tollway and located minutes from area airports and hotels. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 13, 2025 08:01 AM Pacific Daylight Time

Centre for Neuro Skills Launches the “Neuro Skills Podcast,” Focused on Brain Injury Rehabilitation

Centre for Neuro Skills

The Centre for Neuro Skills (CNS) has launched the “Neuro Skills Podcast,” a new series that delves into the latest trends, research and inspiring stories behind the transformative power of brain injury rehabilitation. Debuting on YouTube and Spotify on Monday, March 3, in recognition of Brain Injury Awareness Month, this weekly video series features real-life recovery stories and expert insights on cutting-edge brain injury therapies. The podcast aims to deepen understanding of brain injury rehabilitation and its life-changing possibilities. Hosted by CNS CEO and President David Harrington—a licensed occupational therapist and Certified Brain Injury Specialist with more than 30 years of experience—the podcast will feature conversations with industry leaders, brain injury survivors and experts in post-acute rehabilitation. Notable guests include CNS founder Dr. Mark Ashley and key figures in neurorehabilitation, who will share their expertise and personal experiences. “Brain injury rehabilitation is a journey of resilience, innovation and hope. Through the ‘Neuro Skills Podcast,’ we aim to shed light on groundbreaking therapies, share real recovery stories and provide valuable insights from experts in the field,” says David Harrington, President and CEO of Centre for Neuro Skills and podcast host. “Our goal is to empower patients, families and healthcare professionals with the knowledge and inspiration they need to navigate the path to healing.” Episodes: Episode 1 (available now): A Place of Healing: The Story of CNS When Dr. Mark Ashley’s brother, Steve, became disabled after a devastating event in 1972, conventional rehabilitation therapy gave no hope for recovery. Dr. Ashley, Founder of CNS, made it his mission to find a way for Steve to regain his independence through post-acute rehabilitative care. His recovery became the model for CNS’ ongoing philosophy of practice and our belief that patients don’t plateau, and every brain injury survivor deserves a place to heal and regain independence. Episode 2 (March 10, 2025): Heart Health is Brain Health Pt. 1 Most people don’t know that strokes are brain injuries. This episode explores the connection between heart health and brain health – an often-overlooked aspect of stroke prevention and recovery. Tune in as David Harrington, President and Chief Executive Officer of CNS, and Chris Persel, Regional Director of Clinical Services, Director of Behavior Programming at CNS, dive into key statistics, discuss stroke prevention methods, and explain treatment options that help stroke survivors rebuild their lives and regain independence. Episode 3 (March 17, 2025): Heart Health is Brain Health Pt. 2 Recovery from a brain injury is a lifelong personal journey. David Harrington, President and Chief Executive Officer of CNS, and Chris Persel, Regional Director of Clinical Services, Director of Behavior Programming at CNS, continue their discussion on the importance of engaging patients in rehabilitation through individualized treatments and enriched environments. Episode 4 (March 24): Resilience and Renewal After a Brain Injury How do emotions impact recovery? David Harrington, President and Chief Executive Officer of CNS, and Dr. Gary Seale, Regional Director of Clinical Services at CNS, talk about the significant role that positive emotions play in patient recovery. This episode explores the benefits of being in a positive emotional state: ability to process information quickly and accurately, boost to the immune system, and there’s a less likely chance to trigger the flight or fight response that can lead to risk factors for stroke. Episode 5 (March 31): A Doctor Becomes the Patient: Stroke Survivor Story An unexpected stroke not only impacted Dr. Petersen’s motor skills, but it also changed the way he views the patient experience. A loving father with a background in pediatric emergency medicine, Dr. Petersen overcame physical, emotional, and cognitive deficits during his stroke rehabilitation journey, finding a renewed sense of purpose when he returned to work. In this episode, Dr. Petersen shares his journey from physician to patient and sheds light on the transformative power of rehabilitation. Produced in collaboration with the American Heart Association (AHA) as part of its “Live Fierce campaign,” the “Neuro Skills Podcast” reflects CNS’s commitment to advancing neurorehabilitation and heart health. Through this partnership, CNS and the AHA aim to provide critical information to stroke patients and the broader community, reinforcing the connection between brain health and cardiovascular well-being. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For more information about Centre for Neuro Skills, visit: www.neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. Media, please note: Visual assets, including photos, are available. To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. # # # Contact Details Landis Communications Inc. Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

March 06, 2025 08:01 AM Pacific Standard Time

Image

Bacula Systems Announces Direct Integration with ZFS for Enhanced Backup and Recovery Performance

Bacula Systems

Bacula Systems, a global leader in high-security, high-performance backup and recovery solutions, today announced its latest Use Case: native integration and interoperability with the ZFS file system. This latest enhancement empowers organizations with seamless, high-performance backup and recovery capabilities specifically optimized for ZFS-based infrastructures. The integration of ZFS into Bacula Enterprise enables enterprises and high-performance computing (HPC) environments to take full advantage of ZFS’s advanced storage management features while leveraging Bacula’s robust, scalable, and highly secure backup and disaster recovery capabilities. “Bacula continues to set the standard for reliability, security, and exceptionally high performance in backup and recovery, and our new native ZFS integration further expands our customers’ ability to protect and manage their data in the most efficient way possible. By enabling seamless, high-speed backup and reliable restore operations for ZFS environments, Bacula helps organizations reduce complexity, improve storage efficiency, and maintain strict security and compliance requirements. This is one of a series of important announcements we are making in the high performance file systems space” said Frank Barker, CEO of Bacula Systems. Key Benefits of Bacula’s ZFS Integration: Snapshot-Based Backups: Bacula leverages ZFS snapshots to enable efficient, low-latency backups without impacting system performance. Speed: Bacula’s ZFS capabilities include a fast incremental accelerator for massive file systems and big data volume - all done automatically. Workload Efficiency: Bacula integrates with ZFS's diff feature to quickly backup only necessary/modified files, without needing to scan the entire file system. Advanced Data Protection: Bacula complements its ZFS capabilities with configurable compression, checksum verification, advanced encryption technology, comprehensive ransomware protection, air-gapped architectures, highly flexible immutable storage options and many other highly customizable data protection features for compliance-driven industries. Seamless Scalability: Optimized for large-scale environments, Bacula’s ZFS integration provides ultra-fast backup of snapshot differences of massive datasets. Cost-Efficiency: Organizations can significantly lower their storage costs by leveraging Bacula’s advanced deduplication and compression capabilities in conjunction with Bacula’s efficient data management features. Bacula Systems continues to expand its leadership in providing powerful, customizable, and highly secure backup and recovery solutions tailored for enterprises and HPC environments. The addition of built-in ZFS interoperability underscores Bacula’s commitment to delivering high-performance, flexible, and cost-effective data protection for IT teams managing large and complex workloads. Bacula Systems customers include NASA, Navisite, Texas A&M University, Sky PLC, Warner Bros Discovery, Locaweb and many more. For more information about Bacula’s ZFS integration and enterprise backup solutions, visit www.baculasystems.com. About Bacula Systems: Bacula Enterprise is an exceptionally secure, highly scalable backup and recovery software for large organizations, data centers and MSPs. www.baculasystems.com Contact Details Rob Morrison rob.morrison@baculasystems.com +41 21 641 60 80 rob.morrison@baculasystems.com Company Website https://www.baculasystems.com/

March 05, 2025 07:11 AM Eastern Standard Time

NAVEX One: The Trusted Partner for NIS2 Risk Alignment

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, is pleased to offer the first GRC solution to holistically address NIS2 across training, policies and assessment – all on one platform, NAVEX One. NAVEX continues to provide risk and compliance professionals with the tools they need to align with the latest cybersecurity regulations. As organizations face increasing regulatory demands, NAVEX One integrates policy management, training and risk assessment resources to ensure seamless compliance with the European Union’s Network and Information Security Directive (NIS2). The NIS2 Directive raises the bar for cybersecurity and reporting standards across industries, including banking, healthcare, manufacturing and energy. Organizations must not only comply with these heightened regulations but also ensure their cybersecurity frameworks are strong enough to withstand evolving threats. “NIS2 is a critical milestone in cybersecurity regulation, and organizations need a partner that helps them do more than just check the compliance box,” said A.G. Lambert, chief product officer at NAVEX. “NAVEX One empowers compliance and risk professionals to build a sustainable and proactive approach to cybersecurity, ensuring their programs are compliant and resilient against emerging threats.” NAVEX One serves as an essential tool in the journey toward risk and compliance maturity, helping organizations: Conduct proactive risk assessments to identify and mitigate vulnerabilities Centralize and streamline policy management to meet regulatory expectations Strengthen cybersecurity posture with comprehensive security awareness training Stay ahead of evolving cybersecurity requirements through continuous program improvement and board-ready reporting Extend training, policies and cyber risk practices to align third parties with its cyber risk standards “Organizations today require more than just static risk and compliance checklists—they need dynamic, integrated solutions that evolve with regulatory changes and emerging risks,” said Kyle Martin, vice president of risk solutions at NAVEX. “NAVEX One’s content and capabilities give businesses the confidence to proactively address NIS2 requirements while reinforcing their broader risk management strategies.” By integrating these capabilities within a single platform, NAVEX One simplifies compliance, reduces risk exposure, and supports organizations in building future-proof compliance programs. Click here, for more information on NAVEX One and the NIS2 Directive. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global scott.levesque@navex.com Company Website https://navex.com

February 18, 2025 12:50 PM Eastern Standard Time

SBC Medical (NASDAQ: SBC) Announces New Translation App After Zacks & Sidoti Initiate Coverage, Emphasize Strong Growth

Benzinga

By Gerelyn Terzo, Benzinga With a potential Goldilocks setup in the economy being encouraged in part by a resilient consumer, the broader stock market was hovering near record territory toward the end of last year. Not to be outdone, healthcare-related companies have also been rallying, as evidenced by a gain of almost 20% in the S&P 500 Health Care Sector Index over the past 12 months. One of the stocks that has captured the attention of Wall Street of late is Tokyo-based SBC Medical Group (NASDAQ: SBC), a fast-growing service provider in the burgeoning medical aesthetics market that trades on Nasdaq. Most recently, Zacks Small-Cap Research (SCR) and Sidoti & Company have initiated coverage on the stock. In the October report, Zacks emphasized SBC Medical Group’s expansion efforts comprising both mergers and acquisitions, and organic growth, owing to a growing franchisee network and revenue base buttressed by a strong balance sheet. SBC Medical has been an early mover in Japan’s aesthetic medicine market, which according to the analyst firm, serves as a tailwind for future growth. Zacks SCR believes SBC Medical has “significant value.” Investors who are looking to back a leader in the medical innovation space can learn more about the opportunity in SBC Medical stock here. SBC Medical’s Growing Revenue Chief among the catalysts for the outlook in the report is SBC Medical’s strong reported revenue growth. The company’s revenue has been growing year-over-year, increasing from $174 million in 2022 to $194 million in 2023. Total revenues for the nine months ending Sep. 30, 2024 were $160 million, representing an increase of 23% from $131 million in the same period of 2023, SBC said. As a franchisor, SBC Medical has been growing its footprint amid a rising number of clinics in its vast network that contribute royalty revenue. In addition to Japan, the company also operates clinics in Los Angeles and Ho Chi Minh City, Vietnam, and has set its sights on a global expansion. SBC Medical is also operating in the black, reporting that with net income for the nine months ending Sep. 30, 2024 of $40.1 million, compared to $24.3 million in the same period of 2023. The company’s performance is being fueled by rising royalty income and other revenue streams with high gross margins, it says. Capitalizing On Medical Tourism For New Revenue Opportunities In 2025 The company has announced numerous initiatives to enhance its revenue streams in order to continue to grow its business both domestically and internationally. In January, SBC announced the launch of its proprietary translation app tailored for medical aesthetics staff and the full-scale implementation of its Inbound-Focused Clinics initiative. SBC says this move is designed to address the growing demand for medical tourism and to ensure that international patients can seamlessly experience Japan's advanced medical aesthetic treatments. Within Asia, rising awareness of aesthetic care and the increasing appeal of medical tourism are positioning countries like Japan, South Korea, and Thailand as top destinations for international patients, SBC notes. In Japan, the influx of foreign patients seeking high-quality medical aesthetics continues to rise. SBC alone says it welcomes over 10,000 inbound patients annually, with inquiries surpassing 20,000 each year. China remains a key market driver, though demand from English-speaking regions is also on the rise, the company says. Recognizing this trend, SBC says it is scaling up its operational capacity and implementing innovative solutions to support sustainable growth in this dynamic sector. Striving To Shift Communication With A Specialized Translation App To address language barriers, SBC has developed a translation app tailored specifically for medical aesthetics. It says the app ensures the accurate translation of specialized terminology, facilitating seamless communication between clinic staff and international patients. Currently supporting English and Chinese, the app plays a pivotal role in enabling smooth consultations and pre-treatment explanations. By creating a welcoming environment where language is no obstacle, SBC says it is empowering patients to feel secure and confident in their treatment choices. Future plans include expanding the app's language capabilities and rolling it out across all clinics nationwide, ensuring comprehensive accessibility for a global clientele, SBC noted. SBC Medical’s Valuation: Opportunities And Risks Zacks SCR pointed out that the medical aesthetic market is one that lacks direct competitors despite some companies offering similar services to SBC Medical. As a result, it is difficult to make apples-to-apples comparisons on the stock valuation as analysts typically do. In response, the Zacks analyst has taken a subset of the medical aesthetics space specializing in the healthcare sector to determine a fair valuation. The estimate is contingent upon the company executing on its growth plans as well as a broadening of its initiatives. Zacks SCR is encouraged by SBC Medical’s engagement with the industry, as evidenced by its participation in the Aesthetic Surgery and Laser Society (ASLS) aesthetic medicine conference in Korea held earlier this year. The firm also mentioned SBC Medical’s recently inked partnership with Tokyo-based technology provider B4A, which provides high-tech business solutions. SBC Medical’s mettle was tested amid a business combination with Pono Capital Two, a deal that was completed in Septemb er 2024, paving the way for the stock’s debut on Nasdaq. When it comes to investing, there are no sure things. Zacks SCR and Sidoti have also outlined potential risks that investors might consider. Among them is the uncertain nature of the wider aesthetic medical industry, which is heavily dependent on emerging technology for its growth. SBC’s international presence presents a foreign exchange risk since Its businesses are transacted in Japanese yen but translated into U.S. dollars for reporting purposes, a dynamic that has affected the company’s year-to-date financial performance in 2024. Investors who believe that the benefits outweigh the risks in SBC Medical’s stock can dive deeper into some of the company’s latest developments and offerings here. Featured photo by nattanan23 on Pixabay Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 07, 2025 08:35 AM Eastern Standard Time

Image

Therma Bright Reaffirms Its Position As A Key Player In The $4.2 Billion Compression Market With New Venowave Orders

TBRIF

Last year was a pivotal year for cutting-edge diagnostic and medical device technologies developer Therma Bright Inc. (TSXV:THRM) (OTCQB:TBRIF) for many reasons. Its flagship product, Venowave VW5, a medical compression pump that is lightweight, compact, and battery-operated, which is designed to treat and alleviate the symptoms associated with poor circulation in the lower extremities, received the permanent Healthcare Common Procedure Coding System (HCPCS) code from the U.S. Department of Health & Human Services' Centers for Medicare and Medicaid Services (CMS). The company received the new Venowave VW5 permanent HCPCS Level II code E0683 for this first-of-its-kind solution, as well as a CMS pricing determination marking a critical milestone for the company. This FDA-designated Durable Medical Equipment (DME) device is currently the only Medicare-approved, reimbursable, mobile mechanical compression system available in the US under its HCPCS code E0683, which provides a simple and comfortable mobile treatment solution for patients needing to accelerate post-operative recovery periods while also managing longer-term pain and swelling issues. The codes went live on October 1st, and as expected, this attracted a lot of interest from a number of potential distributors across the country. The company engaged some of these distributors in pilot tests for nationwide launches of the initial Venowave sales program to gauge Medicare/Medicaid reimbursement timelines and billing procedures as well as any rejections that occurred. The distributors had success in the pilot trials, reaffirming the demand for Venowave. For instance, the DME Authority initially took up 25 units, which received 100% reimbursement, and later took 175 more units, which were all also reimbursed, illustrating the traction of Venowave in the market. For context, the DME Authority provides nationally exclusive niche therapy smart devices to hospitals and physician practices with the first-ever white-glove, turn-key, technology-driven capability that delivers true “hospital to home” continuum-of-care coverage. Following the pilot tests, Therma Bright announced it had signed a letter of intent (LOI) for a Venowave distribution program with DME Authority across the US. Through this distribution program, DME Authority would collaborate with multiple tenured and qualified network partners to establish no less than three comprehensive U.S. distribution agreements. As outlined in the LOI, these 'Premier Distributor Partner' contracts would require a minimum foundational inventory purchase of $2 million and collectively commit to a total inventory purchase of $6 million in Venowave VW5 devices within the first six months of 2025, with a minimum equal inventory purchase requirement between Q3 and Q4, 2025. On January 21, Therma Bright announced that it had secured a purchase order for 1,750 Venowave VW5 from the DME Authority, which would offer HCPCS code reimbursements that total about $1.43 million. This purchase order brings both companies one step closer to the outlined LOI that positions DME as a 'Premier Distributor Partner' for the company. Earlier in the year, Therma Bright announced that it had secured an initial purchase order for 100 Venowave VW5 units from another national distribution partner called Valor Medical. The initial purchase order was based on the success of the distributor's pilot tests around the HCPCS code reimbursement program and confirmation that Venowave was indeed a superior product compared to what was in the market. As a new national distribution partner of Therma Bright, Valor Medical looks to fill the immediate needs of its current network of medical practitioners and their patients. According to this distributor and its partners, they receive upwards of 100 doctor referrals per day for vascular compression therapy solutions and have seen great success in securing HCPCS code reimbursements within a normal 30- to 60-day timeframe. Valor Medical and its partners intend to place orders on a regular basis, perhaps every few weeks, as they build greater awareness of the Venowave VW5 solution with their end clients. This initial purchase order for 100 Venowave VW5 units offers HCPCS code reimbursements that total a minimum of $81,955. "We are excited to partner with Therma Bright in offering the Venowave VW5 to our national distribution network," shared Cindy Sebek Quick, Partner of Valor Medical Solutions. "This initial 100-unit purchase will fill the immediate demand of our partners, who anticipate early adoption of this special vascular compression therapy solution.” According to a report from Straits Research, the global compression therapy market was worth about $4.18 billion in 2024 and is projected to grow to $6.72 billion by 2033, representing a CAGR of 7.30%, which bodes well for Therma Bright. With 1,850 Venowave orders in the first month of this year alone and new distribution partners in the pipeline, the company is reaffirming its position as a key player in the US compression market. Moreover, the company’s second product is also helping position it as a key player in the medical device market and creating new potential areas for growth. Therma Bright is currently pursuing a U.S. Food and Drug Administration (FDA) 513(g) request to obtain information regarding the classification and regulatory requirements for its acoustic AI Digital Cough Technology (DCT) as a remote therapeutic monitoring solution. The DCT platform with partner AI4LYF is focused on supporting healthcare decision-making by improving the ability to collect, organize, and display cough and respiratory data for healthcare providers, as well as epidemiologists who are public health workers that investigate respiratory patterns. The company is also looking to get reimbursement codes through CMS that allow for this type of remote therapeutic monitoring device. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and has been compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

February 03, 2025 07:00 AM Eastern Standard Time

Therma Bright Inc. (OTC: TBRIF) Expands in $6.72 Billion Compression Market

TBRIF

In an aging world where healthcare costs are rising, the demand for cost-effective, non-invasive treatments is skyrocketing. One sector seeing a surge in interest is compression therapy, a market projected to grow from $4.18 billion in 2024 to $6.72 billion by 2033. Traditionally dominated by compression stockings and bulky pneumatic devices, the space is undergoing a technological shift toward portable, user-friendly solutions—opening the door for companies developing next-generation devices. One under-the-radar player making moves in this space is Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX). The company’s Venowave VW5, an FDA-cleared, battery-powered compression device, has been gaining traction in the U.S. market, especially following recent reimbursement approvals from Medicare and private insurers. With a growing distribution network, strong early sales, and a huge addressable market, Therma Bright is quickly positioning itself as a compelling small-cap investment in a sector experiencing major tailwinds. With reimbursement momentum building and major distribution deals already in place, is Therma Bright an overlooked gem in the booming compression therapy industry? Let’s take a closer look at the opportunity. Therma Bright Inc.: Advancing Medical Innovation with Venowave VW5 Therma Bright Inc. is a developer and investment partner in advanced diagnostic and medical device technologies. The company focuses on delivering high-quality, innovative healthcare solutions to both consumers and medical professionals. Milestone Achievement: HCPCS Code Reimbursement Secured in Record Time Therma Bright and its nationwide U.S. distribution partners have successfully secured Medicare and Medicaid HCPCS Level II code reimbursements within just 60 days. Since October 1, 2024, over 110 Venowave VW5 units have been deployed across the U.S. in pilot tests, with 25 units already receiving full reimbursement through commercial health networks and federal healthcare programs. The remaining 85 units are anticipated to follow suit soon. Given these strong results, the company has initiated discussions on scaling sales, optimizing delivery logistics, and ramping up manufacturing with its distribution partners. "Our U.S. national distributors are highly impressed with the speed of CMS reimbursements for the Venowave VW5," said Rob Fia, CEO of Therma Bright. "Typically, brand-new HCPCS Level II codes require more time to process, but our code has been efficiently handled within 60 days. This sets a strong precedent for even faster reimbursements in the future and supports our commercialization efforts." Expanding U.S. Distribution with DME Authority Therma Bright has signed a Letter of Intent (LOI) with DME Authority, a Nashville-based distributor, to significantly expand Venowave’s reach. Under this agreement, DME Authority will establish at least three comprehensive distribution agreements, requiring an initial inventory purchase of $2 million. Collectively, these partners will commit to purchasing $6 million worth of Venowave VW5 units within the first six months of 2025, with an equal commitment for Q3 and Q4. DME Authority will also acquire Therma Bright’s remaining in-stock inventory as part of this agreement, ensuring seamless market expansion. "Our strategy to secure Venowave’s HCPCS code was crucial, and the timing couldn’t be better," said Erick Gosse, CEO of DME Authority. "Medicare patients have lacked a mobile mechanical compression solution—Venowave now fills that gap effectively." Product Overview: Venowave VW5 The Venowave VW5 is a compact, battery-operated peristaltic pump designed to improve vascular and lymphatic flow in the lower limbs. It qualifies for Medicare and Medicaid reimbursement under 10 medical indications and is the only Medicare-approved mobile mechanical compression system under HCPCS code E0683. Clinically Proven Benefits: Increases venous blood flow by 64% within 2 minutes and by 88% after 50 minutes of use. Enhanced Mobility: Lightweight (250g), discreet, and wireless, allowing patients to remain active during treatment. FDA-Designated Durable Medical Equipment (DME): Designed for repeated use across multiple patients. Major Purchase Orders Driving Market Expansion Therma Bright continues to strengthen its market presence through key purchase agreements: Valor Medical Solutions: Placed an initial order for 100 Venowave VW5 units following successful pilot trials. The purchase equates to a minimum of $81,955 USD in HCPCS code reimbursements ($117,952 CAD). Valor anticipates increasing its orders biweekly to meet growing demand. DME Authority: Confirmed a major purchase order of 1,750 Venowave VW5 units, totaling $1.43 million USD ($2.05 million CAD) in reimbursements. This milestone further solidifies DME’s role as a Premier Distributor Partner for Therma Bright. Market Outlook: Seizing a Growing Opportunity The global compression therapy market, valued at $4.18 billion in 2024, is projected to grow to $6.72 billion by 2033, representing a CAGR of 7.3%. Therma Bright is well-positioned to capitalize on this expanding market through strategic partnerships, timely reimbursements, and the increasing adoption of Venowave VW5. "With strong distributor commitments, rapid reimbursement processing, and increasing patient demand, we anticipate significant revenue growth in 2025 and beyond," added Rob Fia. Therma Bright remains committed to innovation, accessibility, and enhancing patient care as it scales its commercialization efforts for Venowave VW5 in the U.S. healthcare market. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and has been compensated by Therma Brite to assist in the production and distribution of content related to TBRIF. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website https://razorpitch.com/

January 31, 2025 07:30 AM Eastern Standard Time

Wire Industries Partners with Birches Health to Create Safer, More Responsible Gaming Environment

WagerWire

Wire Industries, Inc., a technology and media company that owns and operates sports betting marketplace WagerWire, announced today that it has partnered with Birches Health, a leading behavioral healthcare company that specializes in the online and confidential prevention and treatment of problem gambling-related challenges. This partnership complements the work Wire Industries has already done to promote responsible gaming by redefining what it means for bettors to have control over their entertainment time participating in real-money gaming and daily fantasy sports. Through this partnership, Wire Industries will propel awareness of responsible gaming and increase bettors’ access to important guidance and tools to ensure they are better informed and aware of the signs of problem gambling and prepared to take steps to address it if they see themselves or others exhibiting those signs. Wire Industries and Birches Health will work together to create clinical materials tailored to the needs of the modern bettor. In addition, Birches Health clinicians will appear on Wire Industries Spaces interviews held live on X.com, Birches Health content will be integrated across the WagerWire app and specific Birches Health and WagerWire co-created resources and tools will live across each partner’s website. “Wire Industries was created with the sole purpose to empower bettors and create an environment of responsible gaming,” said Wire Industries CEO Zach Doctor. “By working with Birches Health, we join ourselves with another innovative company in the industry that is also doing whatever they can to create more awareness, tools and resources for the bettor all while reinforcing our commitment to responsible gaming. We hope others in the industry see this innovation as a way to better the modern bettor and follow suit.” Birches Health is a modern digital healthcare company specializing in the prevention and treatment of behavioral addictions, with a primary focus on gambling disorder and related mental health issues in the United States. Utilizing a three-tiered strategic approach—education, engagement, and treatment—Birches Health offers free online learning modules, self-assessments, tools, and educational content to promote Responsible Gaming and prevent problem behaviors. For individuals in need, personalized treatment plans are crafted and led by licensed, specialized behavioral health clinicians available 24/7. Dedicated to providing convenient and comprehensive care, Birches Health empowers individuals to address behavioral health challenges effectively. “We applaud WagerWire and their team for a focus on making resources and education available and empowering their users to make healthier lifestyle choices.,” said Elliott Rapaport, Founder of Birches Health. “Partnering with Wire Industries to make sure that treatment options through WagerWire, FantasyWire and its other platforms are available to those who may need them creates a culture of sustainable play for all participants.” As part of this initiative, WagerWire and Birches Health are also exploring opportunities to integrate AI-driven tools and personalized support pathways into the WagerWire platform, further enhancing user education and care accessibility. This partnership will also further Wire Industries as an innovative, forward-thinking disruptor in all aspects associated with the gaming world. About Wire Industries Wire Industries Inc was founded with the mission to bring a more efficient, open, and entertaining market to real money gaming of all types, unlocking value for the entire ecosystem. The company was established in 2021 and owns and operates Wire Technologies and Wire Media Group. Wire Technologies is the company’s marketplace division including WagerWire, FantasyWire, PonyWire and ContestWire, while Wire Media Group operates their media network and affiliate marketing division. You can download their flagship product WagerWire in the Apple App Store and Google Play, and find them @WagerWire on Twitter/X, TikTok and LinkedIn, or @WagerWireLive on Instagram. Wire Industries is dedicated to providing a responsible gaming environment. If you think you or someone you know may have a gambling problem, resources are available. Call 1-800-GAMBLER or reach out to their Chief Responsibly Officer Carolina Young directly at live@wagerwire.com. About Birches Health Birches Health provides modern, clinician-led solutions for Responsible Gaming and Problem Gambling care covered by insurance. For more information, visit Birches Health at bircheshealth.com or email partnerships@bircheshealth.com. Contact Details Sterling Randle srandle@hotpaperlantern.com

January 30, 2025 09:01 AM Eastern Standard Time

Image

1 2 3 4 5 6 ... 138

Back